Federated Hermes, Inc. Ardelyx, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.44 $3,578 - $8,735	-6,066 Reduced 67.78%	2,883 $3,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $1,498 - $3,437	2,938 Added 48.88%	8,949 $5,000
Q1 2022 May 13, 2022	BUY	$0.65 - $1.18 $2,830 - $5,137	4,354 Added 262.76%	6,011 $6,000
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $2,104 - $13,537	1,657 New	1,657 $2,000
Q3 2020 Nov 12, 2020	SELL	$5.25 - $7.08 $16,427 - $22,153	-3,129 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.37 - $8.11 $4,741 - $7,161	883 Added 39.31%	3,129 $22,000
Q1 2020 May 13, 2020	BUY	$4.35 - $8.79 $9,770 - $19,742	2,246 New	2,246 $13,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $799M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.